Active, not recruitingPhase 1NCT06050356

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b

Studying Tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Statens Serum Institut
Principal Investigator
Gavin Churchyard, PhD
Aurum Institute
Intervention
H107e(biological)
Enrollment
140 enrolled
Eligibility
18-45 years · All sexes
Timeline
20242026

Study locations (1)

Collaborators

Aurum Institute · Bill and Melinda Gates Foundation · Leiden University Medical Center · South African Tuberculosis Vaccine Initiative

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06050356 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis

← Back to all trials